Johnson and Johnson via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Johnson and Johnson' source. Sun, 21 Mar 2010 15:58:12 +0100 Television Star Alison Sweeney Joins ZYRTEC® to Welcome the Arrival of Spring with the 'Race Against Your Allergies'(Mar 19, 2010) http://www.medworm.com/index.php?rid=3384613&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090319_160000 Ft. Washington, PA (March 19 2010) -- Allergy sufferer and actress Alison Sweeney today joined the makers of the fastest 24-hour over-the-counter (OTC) allergy medicine, ZYRTEC®,for an unusual race to officially welcome the first day of spring and new ZYRTEC® Liquid Gels. The "Race Against Your Allergies," which took place in New York City's Madison Square Park, featured some unusual runners – six, five-foot-tall noses representing some of allergy sufferers' worst symptoms, giving them the chance to "outrun" them this season..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3384613 Fri, 19 Mar 2010 06:04:14 +0100 3384613 Human Performance Institute, Inc. Announces Agreement With Claremont Hotel Club & Spa to Bring its Corporate Athlete® Course to Clients in Bay Area(Mar 17, 2010) http://www.medworm.com/index.php?rid=3376455&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100317_130000 Orlando, FL  (March 17, 2010) – Human Performance Institute, Inc.® (HPI) announced today it has partnered  with Berkeley, California-based Claremont Hotel Club & Spa to host HPI’s Corporate Athlete® Course, an executive leadership training. HPI has offered training at its Orlando, Florida campus since the mid 1990s and will offer training at the Claremont beginning March 22 to better serve its nationwide clientele, which has included senior leaders from dozens of Fortune 500 companies..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3376455 Wed, 17 Mar 2010 05:42:56 +0100 3376455 Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the CYPHER® Sirolimus Drug-Eluting Stent over the Endeavor® Zotarolimus-Eluting Stent(Mar 15, 2010) http://www.medworm.com/index.php?rid=3368500&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100315_160000 This study adds to the unmatched body of safety and efficacy data on the CYPHER® Stent with this comparison to the more recently approved Endeavor® Stent in a contemporary setting..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3368500 Mon, 15 Mar 2010 10:19:52 +0100 3368500 ASP Offers Safety and Convenience to Those Transitioning from 'Just-in-Time' Sterilization to Terminal Sterilization with the Introduction of the ASP OR Solution(Mar 15, 2010) http://www.medworm.com/index.php?rid=3368501&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100315_150000 Denver, CO (March 15, 2010) -- Raising the standards of care in the Operating Room by transitioning from "just-in-time" to terminal sterilization can now be achieved conveniently and effectively with the new Operating Room (OR) Solution from Advanced Sterilization Products (ASP). Now, healthcare professionals have a streamlined process for safely achieving terminal sterilization to meet busy OR needs. The ASP OR Solution will be launched today at the Association of periOperative Registered Nurses' (AORN) 57th Congress in Denver with information and demonstrations at the ASP exhibit Booth 1520..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3368501 Mon, 15 Mar 2010 07:18:13 +0100 3368501 PRILIGY® - New approved medication for Premature Ejaculation available for New Zealand (Mar 12, 2010) http://www.medworm.com/index.php?rid=3356881&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100312_090000 New Zealand Press Association (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3356881 Fri, 12 Mar 2010 14:59:12 +0100 3356881 Introducing NEUTROGENA CLINICAL™ with ION2COMPLEX™ Technology(Mar 11, 2010) http://www.medworm.com/index.php?rid=3352496&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100311_093000 Los Angeles, CA (March 11 2010) -- After years of research and ten new technology patents, Neutrogena®, the #1 dermatologist-recommend skin care brand, introduces NEUTROGENA CLINICAL™, featuring a breakthrough new anti-aging technology known as ION2COMPLEX™ to revitalize the look of collagen-depleted skin..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3352496 Thu, 11 Mar 2010 15:21:48 +0100 3352496 Cordis Unveils Next Generation CoCr Coronary Stent(Mar 11, 2010) http://www.medworm.com/index.php?rid=3352497&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100311_090000 Waterloo, Belgium (March 11, 2010) -- Cordis Corporation today announced the European launch of its next generation of bare metal stent system - PRESILLION™ PLUS. The new stent system, which improves upon the ground-breaking PRESILLION™, features important technological advances designed to gain easier access to distal lesions and help restore the artery's natural form..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3352497 Thu, 11 Mar 2010 14:03:54 +0100 3352497 ACUVUE® Brand Contact Lenses Celebrates Spring with A Chance to Win A $10,000 Shopping Spree(Mar 10, 2010) http://www.medworm.com/index.php?rid=3348811&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100310_090000 Jacksonville, FL (March 10, 2010) – VISTAKON® (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3348811 Wed, 10 Mar 2010 13:40:39 +0100 3348811 Market acceptance of virco®TYPE HIV-1 continues to grow, Virco BVBA to discontinue Antivirogram® for the routine HIV clinical market.(Mar 10, 2010) http://www.medworm.com/index.php?rid=3348812&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100309_093000 Mechelen, Belgium, 8th March 2010: Due to declining demand for the Antivirogram® in the US and other markets, Virco BVBA announced that as of April 26th, 2010, it will no longer offer this service for routine clinical use. The test will remain available for research and the drug discovery and development market..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3348812 Wed, 10 Mar 2010 13:36:13 +0100 3348812 Market acceptance of virco®TYPE HIV-1 continues to grow, Virco BVBA to discontinue Antivirogram® for the routine HIV clinical market.(Mar 9, 2010) http://www.medworm.com/index.php?rid=3345098&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100308_090000 Mechelen, Belgium, 8th March 2010: Due to declining demand for the Antivirogram® in the US and other markets, Virco BVBA announced that as of April 26th, 2010, it will no longer offer this service for routine clinical use. The test will remain available for research and the drug discovery and development market..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3345098 Tue, 09 Mar 2010 14:23:05 +0100 3345098 Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC™ Technology at 68th Annual Meeting of the American Academy of Dermatology(Mar 5, 2010) http://www.medworm.com/index.php?rid=3337160&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100305_090000 CYTOMIMIC(TM) Technology is a trademarked, proprietary technology designed to mimic the body's own bioelectricity (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3337160 Fri, 05 Mar 2010 15:12:29 +0100 3337160 STELARA™ and REMICADE® Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting(Mar 4, 2010) http://www.medworm.com/index.php?rid=3329519&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100304_090000 Miami, FL (March 4, 2010)-- Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010. Cumulative safety data for STELARA™ (up to 18 months) based on pooled analyses of one Phase 2 and two Phase 3 clinical trials will also be presented..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3329519 Thu, 04 Mar 2010 15:05:28 +0100 3329519 AMBI® Skincare and Dreamgirls “Duet” To Celebrate Flawless Beauty(Mar 4, 2010) http://www.medworm.com/index.php?rid=3333557&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100304_100000 New York, New York (March 2, 2010) – The AMBI® Brand is proud to announce its role as the official skincare sponsor of DREAMGIRLS, the glamorous story of aspiration, female empowerment and success.  AMBI® Skincare, a beauty brand committed to empowering and celebrating women of color and providing them skincare solutions for flawless, even toned skin, kicks off the year-long partnership with the new stage version of DREAMGIRLS as it makes its Los Angeles debut at the renowned Ahmanson Theatre with performances through April 12..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3333557 Thu, 04 Mar 2010 07:41:27 +0100 3333557 Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference(Mar 2, 2010) http://www.medworm.com/index.php?rid=3325342&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100302_150000 New Brunswick, NJ (March 2, 2010) -- Johnson & Johnson (NYSE: JNJ) will participate in the 30th Annual Cowen and Company Health Care Conference on Tuesday, March 9th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3325342 Tue, 02 Mar 2010 07:53:39 +0100 3325342 LifeScan Canada Recalls 3 Lots of OneTouch® SureStep® Test Strips(Feb 24, 2010) http://www.medworm.com/index.php?rid=3304807&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100223_160000 Burnaby, British Columbia (February. 24 2010) -- LifeScan Canada Ltd., is conducting a voluntary recall in Canada of 3 lots of OneTouch® SureStep® Test Strips used by people with diabetes to measure their blood glucose levels at home. The test strips are being recalled because they may provide falsely low glucose results when the glucose level is higher than 22.2 mmol/L..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3304807 Wed, 24 Feb 2010 16:31:12 +0100 3304807 LifeScan Recalls Specific Lots of Consumer and Professional OneTouch® SureStep® Test Strips Due To Inaccurate Readings at High Levels(Feb 24, 2010) http://www.medworm.com/index.php?rid=3304808&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100224_150000 Milpitas, CA (February. 24 2010) -- LifeScan, Inc. is conducting a voluntary recall in the United States of eight lots of OneTouch® SureStep® Test Strips, used by people with diabetes to measure their blood glucose levels at home. The test strips are being recalled because they may provide falsely low glucose results when the glucose level is higher than 400 mg/dL..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3304808 Wed, 24 Feb 2010 16:24:58 +0100 3304808 Johnson & Johnson to Participate in RBC Capital Markets' Health Care Conference(Feb 23, 2010) http://www.medworm.com/index.php?rid=3300399&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100223_150000 New Brunswick, NJ (February 23, 2010) -- Johnson & Johnson will participate in the RBC Capital Markets’ Health Care Conference on Tuesday, March 2, 2010, at the New York Palace Hotel, New York, NY.  Dominic Caruso, Vice President, Finance and Chief Financial Officer, will participate in a session scheduled at 11:00 a.m. (Eastern Time)..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3300399 Tue, 23 Feb 2010 07:15:44 +0100 3300399 Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes(Feb 22, 2010) http://www.medworm.com/index.php?rid=3293269&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100222_090000 Cincinnati, OH (February 19, 2010) – Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc.,  settling litigation in Ohio and dismissing pending cases in Delaware.  The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3293269 Mon, 22 Feb 2010 14:48:16 +0100 3293269 New Study Compares Efficacy and Safety of Once-Daily versus Twice-Daily PREZISTA® Regimen in Treatment-Experienced Adult Patients with No PREZISTA Mutations(Feb 17, 2010) http://www.medworm.com/index.php?rid=3281836&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100217_150000 San Francisco, CA (February 17, 2010) – In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority.  These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3281836 Wed, 17 Feb 2010 07:56:32 +0100 3281836 Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA(Feb 16, 2010) http://www.medworm.com/index.php?rid=3278211&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100216_090000 Horsham, PA (February 16, 2010) – Centocor Ortho Biotech Products, L.P. and Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include PROCRIT® (Epoetin alfa), Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa).  The FDA has determined that a REMS is necessary for ESAs to ensure the benefits of these drugs outweigh the risks of shortened overall survival and/or increased tumor progression or recurrence as identified in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid and cervical cancers.&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3278211 Tue, 16 Feb 2010 15:30:18 +0100 3278211 PREZISTA®* Now Approved as Part of Combination Therapy for Pediatric Patients Six Years of Age and Older with HIV(Feb 9, 2010) http://www.medworm.com/index.php?rid=3257066&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100209_090000 Toronto, ON (February 9, 2010) – Tibotec, a division of Janssen-Ortho Inc., announced that Health Canada has approved PREZISTA® (darunavir) for use in children with HIV between the ages of six and 18, dosed twice daily in combination with ritonavir and other antiretroviral agents. PREZISTA® is a protease inhibitor that works by blocking an enzyme critical for the growth of the virus within the body. (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3257066 Tue, 09 Feb 2010 14:10:07 +0100 3257066 Tapentadol Extended Release Data to Be Presented At American Academy of Pain Medicine Annual Meeting(Feb 4, 2010) http://www.medworm.com/index.php?rid=3238010&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100204_090000 San Antonio, TX (February 4, 2010) – Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be discussed during the poster sessions of the 26th Annual Meeting of the American Academy of Pain Medicine (AAPM), February 3-6, 2010 in San Antonio, TX..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3238010 Thu, 04 Feb 2010 13:42:21 +0100 3238010 Spice up your Super Bowl party this year with award-winning chili (Feb 4, 2010) http://www.medworm.com/index.php?rid=3242013&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100204_130000 Toronto, Canada (February 4th 2010) - After weeks of competition and thousands of votes from Canadians across the country, the winner of the second annual ZANTAC® Chili Challenge was announced today. Hosted by Food TV personality, author and restaurateur Anthony Sedlak, the Challenge culminated in a live cook-off competition in Toronto where Mike Callaghan from London, ON, won a trip for two to the Mayan Riviera for his Wiri Wiri Hot Chili recipe..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3242013 Thu, 04 Feb 2010 07:36:38 +0100 3242013 Lines Blurred Between Hair Loss Fact and Fiction(Feb 3, 2010) http://www.medworm.com/index.php?rid=3238011&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100203_090000 Morris Plains, NJ (February 1st, 2010 )-- A new national survey reveals Americans are at a loss when it comes to loss of a different kind: their hair.  The new survey Hair Today, Gone Tomorrow: The Myths & Truths Behind Hair Loss, conducted by Wakefield Research on behalf of the ROGAINE® Brand, reveals a surprising lack of understanding of the prevalence, incidence, causes, and treatments for thinning hair and hair loss..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3238011 Wed, 03 Feb 2010 15:26:35 +0100 3238011 ASP Assists Healthcare Facilities with Transition from the STERIS System 1®(Feb 1, 2010) http://www.medworm.com/index.php?rid=3229847&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100201_093000 (February 1, 2010) – In response to the safety alert issued by FDA on December 3, 2009 regarding the STERIS System 1®, Advanced Sterilization Products (ASP) has developed comprehensive solutions, new resources, financial assistance and educational initiatives to help those complying with the FDA safety alert better navigate through the transition, including an informational Webinar series that launches Friday, February 12..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3229847 Mon, 01 Feb 2010 17:04:55 +0100 3229847 Cordis Corporation Announces Agreement With Boston Scientific To Resolve Certain Coronary Stent Patent Disputes (Feb 1, 2010) http://www.medworm.com/index.php?rid=3226275&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100201_090000 Bridgewater, NJ (February 1, 2010) – Cordis Corporation, a Johnson & Johnson company, announced today that it has reached an agreement with Boston Scientific resolving two Delaware litigations related to Cordis’s Palmaz and Gray patents and Boston Scientific’s Jang patents.  Under the terms of the agreement, Cordis will receive $1.725 billion from Boston Scientific and Johnson & Johnson expects to record the majority of this payment as a special item in the first quarter of 2010..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3226275 Mon, 01 Feb 2010 14:34:13 +0100 3226275 U.S. Food and Drug Administration Approves Labeling Update for PREZISTA® To Include 96-Week Data in HIV-1 Infected Adult Patients(Jan 28, 2010) http://www.medworm.com/index.php?rid=3222207&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100128_100000 Bridgewater, NJ, January 27th, 2010 -- Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies. Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA with ritonavir (r) vs. lopinavir/r in combination with other antiretrovirals (ARVs) for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients, respectively..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3222207 Thu, 28 Jan 2010 15:21:09 +0100 3222207 Patients with Common Heart Rhythm Disorder Experienced Better Outcomes and Fewer Symptoms with Catheter Ablation at One Year Compared to Treatment with Drug Therapy(Jan 27, 2010) http://www.medworm.com/index.php?rid=3214786&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100127_100000 Diamond Bar, CA (January 26, 2010) – According to data appearing today in JAMA (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3214786 Wed, 27 Jan 2010 15:34:30 +0100 3214786 Johnson & Johnson Reports 2009 Fourth-Quarter and Full-Year Results:(Jan 26, 2010) http://www.medworm.com/index.php?rid=3206991&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100125_130000 New Brunswick, NJ (January 26, 2010) – Johnson & Johnson today announced sales of $16.6 billion for the fourth quarter of 2009, an increase of 9.0% as compared to the fourth quarter of 2008. Operational growth was 4.5% and currency contributed 4.5%. Domestic sales were up 2.6%, while international sales increased 15.6%, reflecting operational growth of 6.4% and a positive currency impact of 9.2%. Worldwide sales for the full-year 2009 were $61.9 billion, a decrease of 2.9% over 2008. Operational results declined 0.3% and the negative impact of currency was 2.6%. Domestic sales declined 4.4%, while international sales declined 1.4%, reflecting operational growth of 3.9% and a negative currency impact of 5.3%..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3206991 Tue, 26 Jan 2010 12:30:00 +0100 3206991 The AVEENO® Brand Unveils the AVEENO® Beauty Experience at the 2010 Sundance Film Festival(Jan 21, 2010) http://www.medworm.com/index.php?rid=3196035&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100121_150000 Skillman, NJ (January. 21st, 2009) -- The AVEENO® Brand, recommended by dermatologists for over 60 years and pioneer in ACTIVE NATURALS® ingredients, announces the AVEENO® Beauty Experience at Village at The Yard, the official hospitality suite of the 2010 Sundance Film Festival in Park City, Utah, beginning January 22nd through January 26th. The AVEENO® Brand invites festival-goers to escape from the harsh dry mountain climate and give their hair new life by experiencing the brand's newest product offerings in hair and body care - AVEENO® NOURISH+ STYLE and NOURISH+ SHINE Hair Care Collection and AVEENO® POSITIVELY NOURISHING™ Body Lotions and Washes - before they hit shelves. At the AVEENO® 'STYLE + SHINE' Pop-Up Salon and 'Reshape Your Escape' Oxygen Bar at Sundance new AVEENO... Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3196035 Thu, 21 Jan 2010 07:48:41 +0100 3196035 Ethicon Completes Acquisition of Acclarent(Jan 20, 2010) http://www.medworm.com/index.php?rid=3191641&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100120_150000 Somerville, NJ (January 20, 2010) -- Ethicon, Inc., announced today that it has completed the acquisition of Acclarent, Inc., following clearance under the Hart-Scott-Rodino Antitrust Improvement Act.  Acclarent is a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT).  Ethicon announced its agreement to acquire Acclarent on December 16, 2009..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3191641 Wed, 20 Jan 2010 09:05:18 +0100 3191641 Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2009 Financial Results (Jan 19, 2010) http://www.medworm.com/index.php?rid=3191642&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100119_100000 New Brunswick, NJ (January 19, 2010) - Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, January 26, 2010, to discuss fourth-quarter and full-year 2009 financial results.  The meeting will be hosted by William C. Weldon, Chairman and Chief Executive Officer; Dominic J. Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3191642 Tue, 19 Jan 2010 15:33:52 +0100 3191642 Toric Soft Contact LensStability In Extreme Versions and Postural Positions Can Affect Orientation and Visual Acuity, Study Shows(Jan 18, 2010) http://www.medworm.com/index.php?rid=3181165&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100118_093000 Jacksonville, FL (January 18, 2009) – Toric soft contact lens design affects lens stability and visual acuity, particularly during abnormal gaze movements, such as scanning a newspaper for information, gazing to the extreme side for changing lanes while driving, or playing sports, according to a new study. The research, which compared the effect of gaze direction and posture on toric lens orientation and visual acuity of contact lenses using either an Accelerated Stabilization Design or Prism Ballast Design, is published in the current issue of Contact Lens & Anterior Eye (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3181165 Mon, 18 Jan 2010 14:44:14 +0100 3181165 McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-The-Counter (OTC) Products In The Americas, UAE, and Fiji (Jan 15, 2010) http://www.medworm.com/index.php?rid=3177805&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100115_100000 Fort Washington, PA (January 15, 2010) – In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is voluntarily recalling certain lots of OTC products in the Americas, the United Arab Emirates (UAE), and Fiji (FULL RECALLED PRODUCT LIST BELOW) The company is initiating this recall following an investigation of consumer reports of an unusual moldy, musty, or mildew-like odor that, in a small number of cases, was associated with temporary and non-serious gastrointestinal events.These include nausea, stomach pain, vomiting, or diarrhea. This precautionary action is voluntary and has been taken in consultation with the FDA..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3177805 Fri, 15 Jan 2010 15:21:21 +0100 3177805 PriCara® Launches PrescribeResponsibly.com to Support Responsible Prescribing of Opioid Medicines Used to Treat Pain(Jan 14, 2010) http://www.medworm.com/index.php?rid=3174143&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100114_103000 Raritan, NJ (January. 14th 2010) PriCara,® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today the launch of PrescribeResponsibly.com (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3174143 Thu, 14 Jan 2010 16:51:37 +0100 3174143 VISTAKON® Introduces New 90-Pack For 1-DAY ACUVUE® MOIST® Brand Contact Lenses(Jan 14, 2010) http://www.medworm.com/index.php?rid=3174144&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100114_093000 Jacksonville, FL (January 13, 2010) --  VISTAKON®, Division of Johnson & Johnson Vision Care, Inc., today announced the introduction of a new 90-pack for its 1•DAY ACUVUE® MOIST® (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3174144 Thu, 14 Jan 2010 14:59:59 +0100 3174144 STELARA®* Shows Greater Efficacy than Etanercept for Treatment Of Moderate-To-Severe Plaque Psoriasis(Jan 14, 2010) http://www.medworm.com/index.php?rid=3174145&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20100114_090000 Toronto, ON, (January 14, 2010) —Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel* (etanercept) in the treatment of moderate to severe plaque psoriasis showed a significantly higher clinical response with both doses of STELARA® than etanercept over a 12-week period.  The first-of-its-kind head-to-head study comparing two biologic agents for plaque psoriasis also shows the efficacy of STELARA® among patients in the study who failed to respond to etanercept.  The international study included 18 Canadian sites.  Findings from this study have been published in the January issue of The New England Journal of Medicine (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3174145 Thu, 14 Jan 2010 14:00:57 +0100 3174145 FDA Issues Complete Response Letter for Ceftobiprole (Dec 30, 2009) http://www.medworm.com/index.php?rid=3128009&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091230_090000 Raritan, NJ, (December, 30, 2009) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3128009 Wed, 30 Dec 2009 14:30:18 +0100 3128009 PriCara® Launches PrescribeResponsibly.com to Support Responsible Prescribing of Opioid Medicines Used to Treat Pain (Dec 22, 2009) http://www.medworm.com/index.php?rid=3109845&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091222_093000 Raritan, NJ (Dec. 10, 2009) – PriCara,® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today the launch of PrescribeResponsibly.com (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3109845 Tue, 22 Dec 2009 14:42:32 +0100 3109845 BABYCENTER'S® Baby Names Survey Reveals Aiden and Emma as Top Names of the Decade(Dec 22, 2009) http://www.medworm.com/index.php?rid=3117368&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091222_153000 San Francisco, CA (December 22, 2009) - BABYCENTER® , the leading global online parenting resource, today released the top 10 baby names of the decade with Aiden topping the list for boys and Emma securing the #1 spot for girls. In addition to the top 10 baby names of the decade, BABYCENTER today released the results of the annual Baby Names Survey and Top 100 Baby Names of 2009. Atop the 2009 list for boys is Aiden, for the fifth consecutive year, while Isabella takes the number one spot away from Emma after a four year reign. In 2009 there was an increase in moms using the Web and social media for assistance in deciding on a name. Almost 40% of moms shared their prospective baby name choices with friends on a social network (BABYCENTER Community, Facebook) and 78% of moms have Googled t... Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3117368 Tue, 22 Dec 2009 09:39:28 +0100 3117368 McNeil Consumer Healthcare Announces A Voluntary Nationwide Recall of All Lots Of Tylenol® Arthritis Pain 100 Count with EZ-Open Cap (Dec 21, 2009) http://www.medworm.com/index.php?rid=3109846&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091221_090000 Fort Washington, PA (December 18, 2009) – In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is expanding its voluntary recall to include all available product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3109846 Mon, 21 Dec 2009 14:46:41 +0100 3109846 Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research (Dec 17, 2009) http://www.medworm.com/index.php?rid=3098736&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091217_150000 New Brunswick, NJ (December 17, 2009) -- The Dr. Paul Janssen Award for Biomedical Research has opened the 2010 call for nominations. The $100,000 Award recognizes individuals whose efforts have made significant transformational contributions towards the improvement of human health. Nomination forms are available at pauljanssenaward.com and will be accepted until February 15, 2010. The Award winner is chosen by an independent selection committee of the world's top scientists, which features three new members this year: Robert Langer, Sc.D., Massachusetts Institute of Technology, past Award winner Axel Ullrich, Ph.D., Max Planck Institute of Biochemistry, and Huda Zoghbi, M.D., Baylor College of Medicine..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3098736 Thu, 17 Dec 2009 09:34:29 +0100 3098736 Ethicon Announces Definitive Agreement to Acquire Acclarent (Dec 16, 2009) http://www.medworm.com/index.php?rid=3094715&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091216_150000 Somerville, NJ (December 16, 2009) – Ethicon, Inc., a Johnson & Johnson (NYSE: JNJ) company and a worldwide leader in surgical care, and Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT), today announced a definitive merger agreement whereby Ethicon will acquire Acclarent in an all-cash transaction for approximately $785 million net of estimated cash on hand at time of closing..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3094715 Wed, 16 Dec 2009 10:08:34 +0100 3094715 Tibotec Virco Virology BVBA Acquires LAB TRACKER™ HIV Electronic Medical Record Software System from Ground Zero Software(Dec 15, 2009) http://www.medworm.com/index.php?rid=3091285&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091215_090000 Bridgewater, US (December 15, 2009): Tibotec Virco Virology BVBA today announced the acquisition of LAB TRACKER™ HIV, a customized electronic medical record (EMR) system, from the company Ground Zero Software. (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3091285 Tue, 15 Dec 2009 15:05:44 +0100 3091285 Phase III Study Demonstrates INVEGA® SUSTENNA™ (paliperidone palmitate) Statistically Similar to RISPERDAL® CONSTA® (risperidone) Long-Acting Injection(Dec 10, 2009) http://www.medworm.com/index.php?rid=3073767&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091210_090000 Titusville, NJ (December 10, 2009) – Treatment with once-monthly INVEGA® SUSTENNA™ is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3073767 Thu, 10 Dec 2009 14:35:38 +0100 3073767 Janssen-Cilag Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia(Dec 7, 2009) http://www.medworm.com/index.php?rid=3065469&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091207_120000 Beerse, Belgium (December 4, 2009) -- Janssen-Cilag International NV, has submitted a Marketing Authorisation Application to the European Medicines Agency for paliperidone palmitate, an investigational once-monthly atypical antipsychotic intramuscular injection for the treatment of schizophrenia..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3065469 Mon, 07 Dec 2009 16:58:00 +0100 3065469 Phase III Study of Rivaroxaban Shows That Extending Anticoagulant Treatment by Six or 12 Months Significantly Reduced Risk of Second Symptomatic VTE (Dec 6, 2009) http://www.medworm.com/index.php?rid=3062389&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091206_100000 New Orleans, LA (December 6, 2009) — Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced today that results from the Phase III EINSTEIN-Extension (EXT) clinical trial of the novel oral anticoagulant rivaroxaban showed a significant reduction in the risk of recurrent symptomatic venous thromboembolism (VTE), compared to placebo, in patients who have been treated for a previous deep vein thrombosis (DVT) or pulmonary embolism (PE). The rate of major bleeding was low. The findings were reviewed at today’s press briefing during the 51st Annual Meeting of the American Society of Hematology (ASH), and will be fully presented as part of the late-breaker session of the general meeting at 7:30 AM CST, Tuesday, December 8th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3062389 Sun, 06 Dec 2009 15:57:10 +0100 3062389 Ortho Biotech Oncology Research & Development Data to Be Presented at the 51st Annual Meeting of the American Society of Hematology (ASH) (Dec 4, 2009) http://www.medworm.com/index.php?rid=3054833&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091204_090000 Beerse, Belgium (December 4th, 2009) -- Ortho Biotech Oncology Research & Development, a division of Janssen Pharmaceutica N.V., today announced that data related to several of its oncology compounds will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana, from December 5th to December 8th, 2009..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3054833 Fri, 04 Dec 2009 14:27:44 +0100 3054833 Looking Ahead to AES 2009: New Insights on Comorbidities and other Considerations for Epilepsy Treatment(Dec 4, 2009) http://www.medworm.com/index.php?rid=3054834&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091204_093000 Raritan, NJ (December  4th, 2009)  Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3054834 Fri, 04 Dec 2009 14:20:34 +0100 3054834 New HealthMedia® Digital Coaching™ Programs Address Heart Disease Risk Factors and Help Reduce Health Care Costs(Dec 3, 2009) http://www.medworm.com/index.php?rid=3050537&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091203_090000 Ann Arbor, MI (December 3, 2009) - HealthMedia, Inc., a Johnson & Johnson company, introduced two new Digital Coaching™ programs that help lower cardiovascular disease risk for employee populations. HealthMedia®ACHIEVE™ and HealthMedia® CONTROL™ improve cholesterol and blood pressure self-management through comprehensive and scalable Digital Coaching™ that focuses on behavior change and personal motivation..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3050537 Thu, 03 Dec 2009 14:35:23 +0100 3050537 Tibotec Therapeutics Launches Grace Campaign for Women and People of Color Living With HIV/AIDS (Dec 1, 2009) http://www.medworm.com/index.php?rid=3042515&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091201_090000 Bridgewater, NJ (December 1, 2009) – Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that it is launching a new initiative to raise awareness of issues affecting women and people of color living with HIV/AIDS. Through a comprehensive campaign including local educational events, media outreach and a new Web site, www.TheGraceStudy.com (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3042515 Tue, 01 Dec 2009 14:55:37 +0100 3042515 New Drug Application Submitted To FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain(Dec 1, 2009) http://www.medworm.com/index.php?rid=3046725&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091201_200000 Raritan, NJ (December 1, 2009) – Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3046725 Tue, 01 Dec 2009 13:39:52 +0100 3046725 The AVEENO® Brand Continues Inspiring Communities for a More Naturally Beautiful World(Nov 30, 2009) http://www.medworm.com/index.php?rid=3038245&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091130_090000 Skillman, NJ (November 30th, 2009) -- The AVEENO® Brand continues to make strides towards sustainability with the announcement of exciting new eco-conscious efforts and an alliance that educates consumers on the importance of reducing waste and helping the environment, all building off a foundation set more than three years ago with the brand's AVEENO® Inspires campaign..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3038245 Mon, 30 Nov 2009 14:47:22 +0100 3038245 ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities (Nov 23, 2009) http://www.medworm.com/index.php?rid=3021381&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091123_110000 Irvine, CA (November 23, 2009) – Advanced Sterilization Products (ASP), a leading global infection prevention solution provider, announced today the acquisition by its French affiliate, Apsis S.A.S., of Gloster Europe, a privately held developer of innovative disinfection processes and technologies to prevent healthcare-acquired infections. Terms of the acquisition were not disclosed..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3021381 Mon, 23 Nov 2009 15:49:43 +0100 3021381 Metabolic Effects Significantly Lower With INVEGA® Compared to Olanzapine(Nov 18, 2009) http://www.medworm.com/index.php?rid=3002240&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091118_090000 Beerse, Belgium (November 18th 2009)-- New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy.1 (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=3002240 Wed, 18 Nov 2009 14:39:50 +0100 3002240 National Expressions of Courage Art Contest Unveils Stories of Inspiration(Nov 16, 2009) http://www.medworm.com/index.php?rid=2998018&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091116_090000 Raritan, NJ (November 16, 2009 - Epilepsy and seizures affect nearly 3 million Americans of all ages and in 70 percent of new cases, no cause is apparent. Those who live daily with the condition have no way of knowing when the next seizure will occur, how long it will last or where they will be, often experiencing a roller coaster of emotions as they cope with the condition. The wonder behind the diagnosis, the perseverance in managing it, and the support received through family and friends are some examples of the stories told through artwork in the 2009 Expressions of Courage® art contest, a national art competition inviting people with epilepsy to submit creative artwork conveying their feelings of living with epilepsy..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2998018 Mon, 16 Nov 2009 15:06:22 +0100 2998018 DePuy plans to phase out manufacture at Leeds facility(Nov 12, 2009) http://www.medworm.com/index.php?rid=2987356&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091112_100000 November 12, 2009 - Following a detailed review of its global production requirements versus capacity, DePuy intends to phase out manufacturing at its facility in St. Anthony’s Road, Beeston, Leeds, subject to statutory consultation. The company plans to rationalise its product portfolio to focus on lines that best meet the current and emerging needs of surgeons and patients. Several of these product lines are produced at the Leeds facility.&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2987356 Thu, 12 Nov 2009 15:31:26 +0100 2987356 Analysis Underscores Financial Burden of Mental Illness on Criminal Justice and Health Care Systems(Nov 11, 2009) http://www.medworm.com/index.php?rid=2979572&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091111_083000 Philadelphia, PA (November 11, 2009) – Results from a large, retrospective analysis of inmates with a serious mental illness (SMI) underscores the financial burden of mental illness on the criminal justice and health and human services (HHS) systems, and may provide useful information to policy makers. The results of the analysis, which evaluated patterns of arrest, utilization of services, and corresponding expenditures among nearly 3,800 inmates in a large urban county of Florida, were presented this week at the 137th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2979572 Wed, 11 Nov 2009 13:30:00 +0100 2979572 Longer Prescribed Replacement Intervals Leads to More Stretching of Frequent Replacement Contact Lenses(Nov 11, 2009) http://www.medworm.com/index.php?rid=2979573&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091111_071500 Orlando, FL (November 11, 2009) – Contact lenses prescribed for longer replacement intervals can lead to more extreme over wear (stretching) that could lead to undesirable clinical effects, new research shows..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2979573 Wed, 11 Nov 2009 12:15:00 +0100 2979573 Neutrogena Launches Online Holiday Shopping Destination(Nov 9, 2009) http://www.medworm.com/index.php?rid=2979574&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091109_100000 Los Angeles, CA (November 9, 2009) – Neutrogena®, the #1 dermatologist recommended skincare brand, today launches Neutrogena Holiday (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2979574 Mon, 09 Nov 2009 16:15:18 +0100 2979574 McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL® Arthritis Pain 100 Count with EZ-OPEN CAP(Nov 6, 2009) http://www.medworm.com/index.php?rid=2979575&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091106_120000 Fort Washington, PA (November 6, 2009) - In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is initiating a voluntary recall of a limited number of product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP. McNeil is initiating the recall after identifying an uncharacteristic smell or taste associated with these lots that led to a small number of consumers reporting nausea and related symptoms. This recall includes five product lots only (Full list of lot numbers provided below), and does not include any other lots of TYLENOL® Arthritis Pain Caplet 100 count with EZ-OPEN CAP or any other TYLENOL® Arthritis Pain products. McNeil is implementing this recall as a precaution... Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2979575 Fri, 06 Nov 2009 16:07:11 +0100 2979575 Johnson & Johnson to Participate in Credit Suisse 18th Annual Health Care Conference(Nov 5, 2009) http://www.medworm.com/index.php?rid=2961606&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090405_090000 New Brunswick, NJ (November 5, 2009) -- Johnson & Johnson will participate in the Credit Suisse 18th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2961606 Thu, 05 Nov 2009 14:10:07 +0100 2961606 Ortho Clinical Diagnostics Launches First-of-its-kind Remote Monitoring Center(Nov 4, 2009) http://www.medworm.com/index.php?rid=2961608&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091104_093000 Paris, France (November 4th, 2009) Ortho Clinical Diagnostics (OCD) today announced the launch of a first-of-its-kind 24-7 central command center in Strasbourg, France, that continuously tracks the condition of clinical laboratory instrument performance. The Remote Monitoring Center in Strasbourg provides unique predictive monitoring services to laboratories throughout Europe and the Asia-Pacific region by continuously detecting and tracking potential instrument problems up to 30 days in advance, before they interrupt the ability of the lab to deliver quality test results..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2961608 Wed, 04 Nov 2009 15:17:24 +0100 2961608 Lesser-Known Effects of Smoking Can Play Havoc with Women's Health(Nov 4, 2009) http://www.medworm.com/index.php?rid=2961609&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091104_090000 Toronto, Canada (November 4th, 2009)- Many women are aware that smoking can lead to lung cancer, heart disease and premature death. But a recent survey conducted by Angus Reid on behalf of nicotine replacement therapy brands, NICODERM(R) and NICORETTE(R) reveals that the majority of Canadian women who smoke are not necessarily aware of the host of other impacts that smoking can have on their immediate and longer term health..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2961609 Wed, 04 Nov 2009 15:07:34 +0100 2961609 CONCERTA® in the Classroom: New Data on Attention in Children With ADH(Nov 4, 2009) http://www.medworm.com/index.php?rid=2961607&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091104_150000 >Las Vegas, NV (November 4th, 2009) -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on attention at one hour and through 12.5 hours in children with Attention Deficit Hyperactivity Disorder (ADHD). ADHD is a common and treatable medical condition characterized by inattention, hyperactivity and impulsivity(1) that is estimated to affect about 5 million children(2) in the United States..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2961607 Wed, 04 Nov 2009 09:48:14 +0100 2961607 Johnson & Johnson Announces Restructuring Initiatives for Sustainable Growth (Nov 3, 2009) http://www.medworm.com/index.php?rid=2953088&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091103_073000 New Brunswick, NJ (Nov. 3, 2009) – Johnson & Johnson today announced global restructuring initiatives designed to strengthen the company’s position as the world’s leading global health care company.  The company is taking steps to prioritize its innovation efforts around the many growth opportunities in health care and to execute aggressively on bringing key new products to market.&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2953088 Tue, 03 Nov 2009 12:26:19 +0100 2953088 More Than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen(Oct 31, 2009) http://www.medworm.com/index.php?rid=2948035&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091031_160000 Cork, Ireland (October 31, 2009) –Tibotec announced today results of a new study (VX950-C208), which showed that sustained virologic response (SVR) was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either every 8 hours or every 12 hours,  in combination with standard of care.  Telaprevir, an investigational STAT-C (S (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2948035 Sat, 31 Oct 2009 09:56:45 +0100 2948035 New Studies Demonstrate Benefits of Minimally Invasive Hysterectomy and Colectomy When Compared To Open Surgery(Oct 30, 2009) http://www.medworm.com/index.php?rid=2945835&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091030_150000 Cincinnati, OH (October 26, 2009)– Ethicon Endo-Surgery today announced results from two newly published studies that demonstrate a minimally invasive approach in three common procedures resulted in a reduced rate of complications and lower overall cost of care, including a difference of more than $15,000 on average for minimally invasive colectomies, when compared to open surgery. One study compared two types of minimally invasive hysterectomy procedures to open abdominal hysterectomy1 (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2945835 Fri, 30 Oct 2009 08:45:01 +0100 2945835 Cordis Initiates Nationwide Recall Of CROSSOVER™ Sheath Introducer(Oct 26, 2009) http://www.medworm.com/index.php?rid=2929541&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091026_100000 Bridgewater, NJ. (October 23, 2009) – Cordis Corporation announced today a nationwide voluntary recall of all lots of the CROSSOVER™ Sheath Introducer due to complaints about stretching or fracture of the sheath during use.&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2929541 Mon, 26 Oct 2009 15:59:29 +0100 2929541 Xerox Chairman Anne M. Mulcahy Appointed to Johnson & Johnson Board of Directors (Oct 22, 2009) http://www.medworm.com/index.php?rid=2918455&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091022_110000 New Brunswick, NJ, (October 22, 2009) -- Anne M. Mulcahy, Chairman of Xerox Corporation (NYSE: XRX), today was appointed to the Board of Directors of  Johnson & Johnson (NYSE: JNJ), the world's most broadly based health care products company..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2918455 Thu, 22 Oct 2009 15:45:54 +0100 2918455 More than 1 million Americans suffer from IC(Oct 20, 2009) http://www.medworm.com/index.php?rid=2910823&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091020_090000 Raritan, NJ (October 20, 2009) – More than one million Americans – most of them women –suffer from a painful and little-known bladder condition called interstitial cystitis (IC). To raise awareness and recognize the ongoing struggles of people living with this painful bladder condition, Ortho Women’s Health & Urology™ announces the second annual Interstitial Cystitis Awareness Week (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2910823 Tue, 20 Oct 2009 07:47:53 +0100 2910823 New Study Reveals Link Between Stress Reduction and Increased Fertility(Oct 19, 2009) http://www.medworm.com/index.php?rid=2907240&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091019_104500 Skillman, NJ (October 19, 2009) – Women who participated in a stress management program prior to or during their second IVF cycle had a 160 percent greater pregnancy rate than women who did not participate in a program, according to a study presented today at the American Society for Reproductive Medicine’s 65th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2907240 Mon, 19 Oct 2009 14:45:00 +0100 2907240 New Simponi™ Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis (Oct 19, 2009) http://www.medworm.com/index.php?rid=2907241&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091019_100001 Philadelphia, PA (October 19, 2009) – New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI™ (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2907241 Mon, 19 Oct 2009 14:43:30 +0100 2907241 New Simponi™ Data Show Inhibition of Joint Damage in Patients with Rheumatoid Arthritis and Psoriatic Arthritis(Oct 19, 2009) http://www.medworm.com/index.php?rid=2907242&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091019_100000 Philadelphia, PA – October 19, 2009 – Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI™ (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA). Radiographic analyses showed that treatment with SIMPONI resulted in a statistically significant reduction in change from baseline in structural damage as measured using the van der Heijde-Sharp (vdH-S) scoring method, an X-ray measure of changes in joint destruction, including joint erosion and joint space narrowing. These one-year data were presented at the 2009 American College of Rheumatology Annual Scientific Meeting..... (Source: Jo... Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2907242 Mon, 19 Oct 2009 14:31:53 +0100 2907242 Health Canada Endorsed Important Safety Information on INTELENCE* (etravirine)(Oct 19, 2009) http://www.medworm.com/index.php?rid=2907243&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091019_090000 Toronto (October 19, 2009) - Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in collaboration with Health Canada, would like to inform patients of important safety information regarding severe skin reactions in patients receiving HIV combination therapy including INTELENCE (etravirine) tablets. Reports have included severe allergic reactions sometimes accompanied by liver failure, and one report of death..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2907243 Mon, 19 Oct 2009 14:08:56 +0100 2907243 Biosense Webster Receives FDA Clearance For The CARTO® 3 System(Oct 15, 2009) http://www.medworm.com/index.php?rid=2897151&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091015_093000 Diamond Bar, CA (October 15, 2009) – (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2897151 Thu, 15 Oct 2009 14:44:24 +0100 2897151 Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System(Oct 15, 2009) http://www.medworm.com/index.php?rid=2897152&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091015_090000 Raritan, N.J. (Oct. 14, 2009) - Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.  This is the first HIV diagnostic assay approved for an integrated system in the United States, allowing laboratories to run HIV and other routine tests on a single testing platform and eliminating the need for expensive batch testing of multiple patient samples..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2897152 Thu, 15 Oct 2009 14:37:10 +0100 2897152 Johnson & Johnson Reports 2009 Third-Quarter Results:(Oct 13, 2009) http://www.medworm.com/index.php?rid=2885084&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091013_074500 New Brunswick, NJ (October 13, 2009) – Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2885084 Tue, 13 Oct 2009 11:40:00 +0100 2885084 Ethicon Endo-Surgery Introduces Innovation-Enabling Solutions Across the Spectrum of Surgery at ACS(Oct 12, 2009) http://www.medworm.com/index.php?rid=2885085&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091012_113000 Chicago, IL (October 12, 2009) -- Ethicon Endo-Surgery introduced several novel surgical solutions at the 95th Annual Clinical Congress of the American College of Surgeons, highlighting how the company is enabling innovation through collaboration across the continuum of surgical techniques and options. A surgeon-only online community, first-of-its-kind technology to improve surgical visualization, a new Access System for single-site laparoscopy (SSL), and an articulating endoscopic linear cutter are among the latest additions to the Ethicon Endo-Surgery portfolio of solutions that respond to surgeon and patient needs..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2885085 Mon, 12 Oct 2009 15:16:09 +0100 2885085 Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS™(Oct 8, 2009) http://www.medworm.com/index.php?rid=2874210&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091008_120000 Cincinnati – (October 8, 2009) – Ethicon Endo-Surgery today announced the company won a Gold 2009 International Design Excellence Award (IDEA) for the research and design process used in the development of the HARMONIC FOCUS™ Curved Shear. The company was recognized among thousands of entries for its innovative use of four types of research, including extensive collaboration with surgeons across the globe to identify specific unmet needs in thyroid procedures, which played a critical role in the final product. This award is the latest among several other recent honors Ethicon Endo-Surgery has received for products in the HARMONIC® ultrasonic energy delivery device..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2874210 Thu, 08 Oct 2009 15:47:30 +0100 2874210 Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Medical Devices & Diagnostics Business (Oct 6, 2009) http://www.medworm.com/index.php?rid=2867716&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091006_130000 New Brunswick, NJ (October 6, 2009) - Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Oct. 13, 2009, to discuss third-quarter financial results and review its Medical Devices & Diagnostics business.  The meeting will be hosted by Alex Gorsky, Worldwide Chairman, Medical Devices & Diagnostics; Dominic Caruso, Vice President, Finance and Chief Financial Officer; and Louise Mehrotra, Vice President, Investor Relations..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2867716 Tue, 06 Oct 2009 07:40:30 +0100 2867716 SIMPONI™ (golimumab) Receives European Approval As Once-Monthly Subcutaneous Anti-Tnf For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis With Novel Smartject™ Autoinjector(Oct 6, 2009) http://www.medworm.com/index.php?rid=2867717&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091006_120000 Horsham, PA and Kenilworth, NJ, (October 6, 2009) – Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the European Commission has approved SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS).&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2867717 Tue, 06 Oct 2009 07:23:40 +0100 2867717 Veridex’s Cellsearch® Circulating Tumor Cell Test Wins Prestigious Prix Galien Award for Best Medical Technology(Oct 1, 2009) http://www.medworm.com/index.php?rid=2849256&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091001_090000 Raritan, N.J., (Oct. 1, 2009) – Veridex, LLC announced today that the CellSearch® Circulating Tumor Cell (CTC) Test was honored with the first-ever Prix Galien USA 2009 Award for Best Medical Technology.   &#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2849256 Thu, 01 Oct 2009 14:29:43 +0100 2849256 McNeil Consumer Healthcare, a division of Johnson & Johnson Inc. (Canada) announces a voluntary nationwide recall of Adult TYLENOL® Cold Rapid Release Daytime/Nighttime Combination package due to print error(Sep 30, 2009) http://www.medworm.com/index.php?rid=2844793&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090930_090000 Mar, ON, (September. 29, 2009) (Canada NewsWire via COMTEX News Network) -- McNeil Consumer Healthcare, a Division of Johnson & Johnson Inc. (Canada) is voluntarily recalling units of Adult TYLENOL® Cold Rapid Release Daytime/Nighttime Combination 18 count packages, an over-the-counter cold product, due to a print error in the French copy of the Nighttime product foil blister backing. The company is taking this action in consultation with Health Canada..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2844793 Wed, 30 Sep 2009 13:33:44 +0100 2844793 Cordis Corporation Announces Agreement with Boston Scientific to Settle Selected Stent Litigation Cases(Sep 29, 2009) http://www.medworm.com/index.php?rid=2844794&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090929_150000 Bridgewater, NJ -- September 29, 2009 – Cordis Corporation (“Cordis”) announced today that it has reached an agreement with Boston Scientific (“Boston”) resolving its Palmaz infringement suit relating to Boston’s NIR stent, settling several other cardiology-related cases relating to patents in the Ding, Kastenhofer, Palmaz, and Fontirroche patent families, and exchanging paid-up licenses for certain intellectual properties.  In addition, Boston will pay Cordis Corporation $716.3 million on October 1. Johnson & Johnson expects to record the majority of this payment as a special item during the fourth quarter..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2844794 Tue, 29 Sep 2009 08:55:16 +0100 2844794 AMBI® Skincare Announces Winners of the AMBI® Scholarship in Science & Medicine(Sep 28, 2009) http://www.medworm.com/index.php?rid=2844795&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090928_120000 Skillman, NJ (Sept. 28, 2009) AMBI® Skincare proudly announces the five winners of the AMBI® Scholarship in Science & Medicine, a scholarship program designed to recognize, reward and support African American and Hispanic women in fields in which they are currently underrepresented..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2844795 Mon, 28 Sep 2009 15:01:30 +0100 2844795 Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment(Sep 28, 2009) http://www.medworm.com/index.php?rid=2837772&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090928_090000 New Brunswick, NJ and Leiden, the Netherlands (September 28, 2009) – Johnson & Johnson (NYSE: JNJ) and Crucell, N.V., (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Crucell have entered into a strategic collaboration focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2837772 Mon, 28 Sep 2009 13:34:37 +0100 2837772 STELARA™ (Ustekinumab) Receives Fda Approval For Treatment Of Moderate To Severe Plaque Psoriasis With Four-Times-A-Year Maintenance Dosing (Sep 25, 2009) http://www.medworm.com/index.php?rid=2833576&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090925_150000 Horsham, PA (September 25, 2009) – Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA™ (ustekinumab) for the treatment of adult patients 18 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.  The efficacy and safety of STELARA were evaluated in one of the largest clinical development programs for a biologic medication in the treatment of psoriasis..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2833576 Fri, 25 Sep 2009 06:02:12 +0100 2833576 NEVO™ Sirolimus-eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months than Taxus® Liberte® Stent(Sep 24, 2009) http://www.medworm.com/index.php?rid=2830697&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090924_160000 San Francisco, CA (September 24, 2009) – At six months, patients receiving the NEVO™ Sirolimus-eluting Coronary Stent reported significantly less chest pain (also known as angina)  than those receiving the Taxus® Liberte® Stent.  Patients also reported improvements in their overall quality of life.  These data demonstrate the important benefits of drug-eluting stents in reducing chest pain in patients with coronary artery disease..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2830697 Thu, 24 Sep 2009 08:33:06 +0100 2830697 New Clinical Trial Results Show Germ-Killing Action of LISTERINE® Antiseptic Kills Germs in the Mouth Before They Travel To the Bloodstream(Sep 24, 2009) http://www.medworm.com/index.php?rid=2830698&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090924_120000 Morris Plains, NJ (September 24, 2009) — The results of a new clinical study demonstrate that the plaque and gingivitis germ-killing action of LISTERINE® Antiseptic significantly reduces the amount of germs that travel from the mouth to the bloodstream in people with mild to moderate gingivitis. These findings are significant, as emerging science suggests that gingivitis, if left untreated and allowed to progress to advanced gum disesase, could contribute to broader health problems such as diabetes, cardiovascular disease, and pneumonia..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2830698 Thu, 24 Sep 2009 05:24:44 +0100 2830698 Statewide Partnerships Address Local Nursing Shortage(Sep 23, 2009) http://www.medworm.com/index.php?rid=2822610&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090923_083000 Baltimore, MD (September 23, 2009) - As part of its ongoing commitment to help alleviate the nursing shortage in Maryland and across the United States, The Johnson & Johnson Campaign for Nursing’s Future will host the “Promise of Nursing for Maryland” gala on Thursday, September 24 to raise funds to help ease the shortage throughout the region. One hundred percent of the event’s proceeds will support regional nursing school grants, faculty fellowships and student scholarships..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2822610 Wed, 23 Sep 2009 13:30:01 +0100 2822610 Janssen-Cilag's STELARA® (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis(Sep 23, 2009) http://www.medworm.com/index.php?rid=2822611&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090923_080000 HIGH WYCOMBE, England (September 23, 2009)-- STELARA (ustekinumab) has today been approved by the National Institute for Health and Clinical Excellence (NICE) as a treatment option for adults with moderate to severe plaque psoriasis,(1) a notoriously difficult-to-treat kin condition for which many patients report feeling dissatisfied and frustrated with existing treatment options.(2..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2822611 Wed, 23 Sep 2009 13:19:49 +0100 2822611 ASP Launches 24-Minute EXPRESS Cycle for the STERRAD® 100NX™ System(Sep 21, 2009) http://www.medworm.com/index.php?rid=2817499&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090921_090000 Irvine, CA (September 21, 2009) -- Advanced Sterilization Products (ASP) announced today the availability of the STERRAD® 100NX™ System EXPRESS Cycle in the Europe, Middle East and Africa (EMEA) Region. This new, faster cycle is designed for terminal surface sterilization of da Vinci® 3D endoscopes, as well as rigid telescopes, rechargeable batteries and many other devices. The EXPRESS cycle fulfills urgent sterilization needs without the damage associated with other sterilization modalities..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2817499 Mon, 21 Sep 2009 13:30:55 +0100 2817499 The Makers Of LISTERINE® And REACH® TOTAL CARE Products Unveil A New Laugh-Out-Loud Book Benefiting The National Children’s Oral Health Foundation®: America's Toothfairy(Sep 17, 2009) http://www.medworm.com/index.php?rid=2802673&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090917_120000 Morris Plains, NJ – (September 17, 2009) – The makers of LISTERINE® and REACH® TOTAL CARE introduce an exclusive, limited-edition book titled “36 ½ Reasons to Laugh: A Slice of Life.”  This custom book is inspired by funny moments in everyday life – including dating mishaps, office gaps, and family antics – and features a foreword authored by ABC’s Desperate Housewives (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2802673 Thu, 17 Sep 2009 16:32:25 +0100 2802673 Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment (Sep 17, 2009) http://www.medworm.com/index.php?rid=2802674&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090917_090000 New Brunswick, N.J., and Dublin, Ireland, September 17, 2009 – Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP).  In addition, Johnson & Johnson, through its affiliate, Janssen Pharmaceutical, has invested $885 million in exchange for newly issued American Depositary Receipts (ADRs) of Elan, representing 18.4% of Elan’s outstanding ordinary shares..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2802674 Thu, 17 Sep 2009 13:36:51 +0100 2802674 Resolve to Sweat Smart this Fall with Proper Pain Prevention - and Treatment (Sep 14, 2009) http://www.medworm.com/index.php?rid=2792122&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090914_090000 Toronto, Canada (September 14th 2009) The month of September marks more than just the end of summer vacation and back to school. It's also a time for starting new routines and for many Canadians, a time to renew health and lifestyle resolutions including increased physical activity and getting back to the gym. Yet, many of the new and renewed fitness fanatics this fall may not realize that rushing into a new exercise program can result in unnecessary pains, strains and even injury..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2792122 Mon, 14 Sep 2009 13:26:44 +0100 2792122 Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL® for the Treatment of Advanced Breast Cancer(Sep 11, 2009) http://www.medworm.com/index.php?rid=2789695&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090909_213000 Horsham, Pa., September 10, 2009 – Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection)in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2789695 Fri, 11 Sep 2009 14:06:30 +0100 2789695 FDA Issues Complete Response Letter for Trabectedin Combined With DOXIL(Sep 10, 2009) http://www.medworm.com/index.php?rid=2789696&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090910_130000 Horsham, PA (September 10, 2009) – Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL® (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer.  The agency has requested additional information, including overall survival data from the company’s ongoing pivotal trial and additional clinical pharmacology studies..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2789696 Thu, 10 Sep 2009 06:15:02 +0100 2789696 Pro Quarterback David Garrard Aims to Score Big for Crohn's Disease During the 2009 Football Season(Sep 9, 2009) http://www.medworm.com/index.php?rid=2776744&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090909_120000 Horsham, PA (September 9, 2009) – Centocor Ortho Biotech Inc. announced today that the In the Zone for Crohn’s program with David Garrard, quarterback for the Jacksonville Jaguars® will continue this football season to raise awareness and provide funding for Crohn’s disease research, education and support. Building on the success of last year’s program, which raised $170,000 for the Crohn’s & Colitis Foundation of America (CCFA), Centocor Ortho Biotech will again make a donation of $10,000 to the CCFA for each touchdown Garrard scores, passing or rushing, during the 2009 NFL season..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2776744 Wed, 09 Sep 2009 15:55:04 +0100 2776744 CONCERTA® (methylphenidate HCI) Launches Mobile Web Experience To Provide Tools and Support for ADHD Awareness (Sep 9, 2009) http://www.medworm.com/index.php?rid=2776745&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090909_090000 Titusville, NJ (Sept. 9, 2009) — Attention Deficit Hyperactivity Disorder (ADHD) is estimated to impact up to 20 percent of children1 (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2776745 Wed, 09 Sep 2009 13:50:07 +0100 2776745 Depuy Orthopaedics, Inc. And Depuy Mitek, Inc. Launch New Web Site for Primary Care Providers On Chronic Shoulder Pain (Sep 9, 2009) http://www.medworm.com/index.php?rid=2780641&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090909_130000 Warsaw, IN (September 9, 2009) – (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2780641 Wed, 09 Sep 2009 05:04:47 +0100 2780641 Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research (Sep 8, 2009) http://www.medworm.com/index.php?rid=2773760&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090908_120000 Beerse, Belgium – September 8, 2009 – Johnson & Johnson today honored the career achievements of Axel Ullrich, Ph.D., with the 2009 Dr. Paul Janssen Award for Biomedical Research. Dr. Ullrich received this award for his scientific discoveries that led to innovative new drugs including Herceptin® (trastuzumab),* a personalized medicine therapy, which was the first to target a specific type of breast cancer. Dr. Ullrich also led the development of the first drug created through gene cloning, a recombinant human insulin for treating diabetes which arguably marked the beginning of the biotechnology age. Dr. Ullrich, director for the Department of Molecular Biology, Max Planck Institute of Biochemistry in Germany, was presented with the Award during a ceremony at The Dr. Paul Janssen R... Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2773760 Tue, 08 Sep 2009 16:06:32 +0100 2773760 Johnson & Johnson to Participate in Morgan Stanley Global Healthcare Unplugged Conference(Sep 8, 2009) http://www.medworm.com/index.php?rid=2776746&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090908_150000 New Brunswick, NJ (September 8, 2009) -- Johnson & Johnson (NYSE:JNJ) will participate in the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2776746 Tue, 08 Sep 2009 08:34:06 +0100 2776746 Ethicon Endo-Surgery Expands REALIZE™ Solution (Sep 8, 2009) http://www.medworm.com/index.php?rid=2776747&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090908_130000 Cincinnati, OH (September 8th, 2009) – (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2776747 Tue, 08 Sep 2009 06:07:38 +0100 2776747 Depuy Orthopaedics, Inc. And Depuy Mitek, Inc. Launch New Web Site for Primary Care Providers on Chronic Shoulder Pain (Sep 4, 2009) http://www.medworm.com/index.php?rid=2767800&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090904_150000 Warsaw, IN – (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2767800 Fri, 04 Sep 2009 16:00:00 +0100 2767800 First Patient Enrolled In CYPRESS, A Dual Antiplatelet Therapy Trial with the CYPHER® Sirolimus-Eluting Coronary Stent(Aug 31, 2009) http://www.medworm.com/index.php?rid=2755478&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090831_130000 Bridgewater, NJ, (August 31, 2009) – (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2755478 Mon, 31 Aug 2009 05:46:04 +0100 2755478 Are Parents A Barrier To Contact Lens Wear By Children?(Aug 25, 2009) http://www.medworm.com/index.php?rid=2732524&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090825_080000 Jacksonville, FL  (August 25, 2009) – Parents and children don’t always see eye to eye when it comes to vision correction, according to a survey of parents of vision-corrected children 8-17 years old conducted by Fairfield Research among members of the Good Housekeeping Reader Advisory Panel on behalf of ACUVUE® Brand Contact Lenses..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2732524 Tue, 25 Aug 2009 12:59:21 +0100 2732524 FDA Issues Complete Response Letter for Carisbamate(Aug 21, 2009) http://www.medworm.com/index.php?rid=2722293&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090821_150000 Titusville, NJ  (Aug. 21, 2009)  -- The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2722293 Fri, 21 Aug 2009 10:03:39 +0100 2722293 FDA Advisory Panel Recommends Approval of First Ceramic-On-Metal Implant for Hip Replacement(Aug 19, 2009) http://www.medworm.com/index.php?rid=2714426&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090819_090000 Warsaw, IN (August 18, 2009) – (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2714426 Wed, 19 Aug 2009 14:42:41 +0100 2714426 Re-launch of Psychiatry 24x7.com(Aug 17, 2009) http://www.medworm.com/index.php?rid=2707200&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090817_090000 Beerse, Belgium (August 17, 2009)-- Janssen-Cilag is delighted to announce the re-launch of their popular website Psychiatry24x7. The site, which has been running for 7 years, has been completely re-designed to make it more user friendly and include a broader range of information for people with mental health problems, in a more engaging format..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2707200 Mon, 17 Aug 2009 07:47:39 +0100 2707200 Ethicon Introduces New Product Enhancement and Packaging for BIOPATCH® To Improve Ease of Application for Patients with Catheters(Aug 11, 2009) http://www.medworm.com/index.php?rid=2714427&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090811_110000 Somerville, NJ (August 11, 2009) Ethicon, Inc., a Johnson & Johnson Company, today announced that BIOPATCH® Protective Disk with CHG (chlorhexidine gluconate) will include new design elements and updated packaging to make it easier for surgeons, nurses and other healthcare providers to apply the product correctly around catheters to reduce the risk of catheter-related bloodstream infections (CRBSIs). Distribution of BIOPATCH® with the enhanced design and packaging began on August 10, 2009 and the product will be available nationwide by mid-August..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2714427 Tue, 11 Aug 2009 15:21:08 +0100 2714427 Worldwide Gap Between Vision Care Attitudes & Behavior(Aug 6, 2009) http://www.medworm.com/index.php?rid=2677111&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090806_090000 Jacksonville, FL (August 6, 2009) – Across cultures and national boundaries, sight is valued as the most important of the five senses. Yet, new research reveals that across the world, nearly half (44%) share the misguided belief that seeing well translates to good eye health. This and other findings confirm a large global gap between vision care attitudes and behavior which may be preventing people from seeking proper treatment and diagnosis for them and their children..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2677111 Thu, 06 Aug 2009 14:21:24 +0100 2677111 FDA Approves INVEGA® SUSTENNA™ for the Acute and Maintenance Treatment of Schizophrenia(Jul 31, 2009) http://www.medworm.com/index.php?rid=2659575&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090731_153000 Titusville, NJ (July 31, 2009) – The U.S. Food and Drug Administration today approved INVEGA® SUSTENNA™ (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, will market INVEGA SUSTENNA in the U.S..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2659575 Fri, 31 Jul 2009 09:12:14 +0100 2659575 INVEGA® Approved as the First and Only Treatment for Schizoaffective Disorder(Jul 31, 2009) http://www.medworm.com/index.php?rid=2659576&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090731_150000 Titusville, NJ (July 31, 2009) –The U.S. Food and Drug Administration (FDA) today approved the first and only antipsychotic for the acute treatment of schizoaffective disorder. INVEGA® (paliperidone) extended-release tablets were approved for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants. INVEGA® was approved in 2006 for the treatment of schizophrenia. Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, markets INVEGA® in the U.S..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2659576 Fri, 31 Jul 2009 08:46:31 +0100 2659576 New Way RA™ Talk Show Premieres Online For People Living With Rheumatoid Arthritis (RA)(Jul 29, 2009) http://www.medworm.com/index.php?rid=2652174&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090729_083000 Horsham, PA (July 29, 2009) - (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2652174 Wed, 29 Jul 2009 13:23:41 +0100 2652174 Ethicon Endo-Surgery Holds Metabolic Surgery Scientific Forum Featuring Research By Top Scientists(Jul 29, 2009) http://www.medworm.com/index.php?rid=2652175&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090729_080000 >Cincinnati, OH (July 28, 2009) -- Ethicon Endo-Surgery held a scientific symposium at the 26th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) where four leading researchers shared innovative thinking coupled with mounting data about how the biochemical and endocrine effects of metabolic surgery is shaping research, treatment and health care policy for patients battling the co-morbid conditions associated with obesity, particularly Type 2 diabetes..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2652175 Wed, 29 Jul 2009 13:14:08 +0100 2652175 Johnson & Johnson Announces 2008 Sustainability Report(Jul 23, 2009) http://www.medworm.com/index.php?rid=2636669&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090723_140000 New Brunswick, NJ (July 23, 2009) -- Johnson & Johnson (NYSE: JNJ), today announced availability of the Johnson & Johnson 2008 Sustainability Report http://www.jnj.com/connect/caring/environment-protection/ (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2636669 Thu, 23 Jul 2009 07:58:27 +0100 2636669 FDA Approves VITROS® Anti-HCV Assay for Use on VITROS 5600® Integrated AND VITROS 3600® Immunodiagnostic Systems(Jul 21, 2009) http://www.medworm.com/index.php?rid=2624103&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090721_113000 Raritan, NJ (July 21, 2009) - Ortho Clinical Diagnostics today announced the U.S. Food and Drug Administration (FDA) approval of the VITROS® Anti-HCV assay for use on the VITROS 5600® Integrated and 3600® Immunodiagnostic Systems.  This approval marks a major milestone in the successful launches of Ortho Clinical Diagnostics’ clinical laboratory testing platforms, and enables the consolidation of hepatitis C testing with routine assays on the VITROS® 5600 Integrated System..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2624103 Tue, 21 Jul 2009 15:13:41 +0100 2624103 Ortho Clinical Diagnostics Launches 24-Hour Remote Monitoring Center (Jul 21, 2009) http://www.medworm.com/index.php?rid=2624104&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090721_110000 Raritan, NJ (July 21, 2009) – Ortho Clinical Diagnostics today announced the launch of its Remote Monitoring Center, the first 24-7 central command center in the in vitro (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2624104 Tue, 21 Jul 2009 15:06:54 +0100 2624104 New e.p.t.®/BabyCenter® Fertility Report Reveals 70 Percent of Moms Want Tighter Regulation on In-Vitro Fertilization(Jul 20, 2009) http://www.medworm.com/index.php?rid=2618773&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090720_100000 Skillman, NJ (July 20, 2009) -- The pop culture phenomenon of mother of octuplets Nadya Suleman and "Jon & Kate Plus 8" has American families buzzing about the morality of multiple births, conceived by in-vitro fertilization (IVF). The recent e.p.t® /BabyCenter® Fertility Report* found that 7 out of 10 moms and expectant mothers surveyed believe that public visibility of large families and multiple births are giving people a glamorized view of raising children. These women want tougher regulations on IVF, stating "there needs to be an authority such as a doctor, psychiatrist, social worker, or counselor that makes practical decisions when it comes to fertility treatments...... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2618773 Mon, 20 Jul 2009 14:18:22 +0100 2618773 96-Week Safety And Efficacy Findings Presented For INTELENCE™ (etravirine) As Part Of HIV Combination Therapy (Jul 20, 2009) http://www.medworm.com/index.php?rid=2618774&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090720_090000 Bridgewater, NJ (July 20, 2009)—Ninety-six week pooled results from two  Phase 3 studies (DUET-1 and DUET-2) showed that significantly more treatment-experienced HIV-1-infected adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) resistance had an undetectable viral load (<50 HIV-1 RNA copies/mL) while taking INTELENCE™ (etravirine) tablets plus background regimen (BR) compared with placebo plus BR.  These findings were presented today at the 5th (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2618774 Mon, 20 Jul 2009 13:22:42 +0100 2618774 New HIV Study Shows That Large Numbers Of Women And People Of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies(Jul 20, 2009) http://www.medworm.com/index.php?rid=2618775&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090720_093000 Bridgewater, NJ (July 20, 2009) – Data from a historic HIV study demonstrate that it is possible to recruit large numbers of women, African Americans and Latinos into U.S.-based HIV-1 treatment studies.  The study, known as GRACE, is the largest study to date in treatment-experienced adult women with HIV-1 to examine gender and race differences in response to an HIV-1 therapy – PREZISTA® (darunavir) coadministered with ritonavir as part of combination therapy.  GRACE findings were presented today at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa. &#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2618775 Mon, 20 Jul 2009 13:22:33 +0100 2618775 Tibotec Pharmaceuticals Announces Agreement To Develop And Commercialize A New Fixed-Dose Combination Of Tmc278 And Truvada® With Gilead Sciences(Jul 16, 2009) http://www.medworm.com/index.php?rid=2608482&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090716_150000 Cork, Ireland, July 16, 2009 – Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) and Gilead’s Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naïve adult patients with HIV-1. Fixed-dose combinations contain multiple medicines formulated into one tablet and help to simplify HIV therapy..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2608482 Thu, 16 Jul 2009 08:11:15 +0100 2608482 Centocor Ortho Biotech Statement on FDA ODAC Opinion Regarding DOXIL® For Treatment of Advanced Breast Cancer(Jul 15, 2009) http://www.medworm.com/index.php?rid=2604438&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090715_140000 Horsham, PA (July 15, 2009)– Based on the data presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of DOXIL® (doxorubicin HCI liposome injection) and docetaxel did not provide a sufficient benefit-risk profile for first-line treatment of locally advanced or metastatic breast cancer..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2604438 Wed, 15 Jul 2009 08:39:18 +0100 2604438 Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer (Jul 15, 2009) http://www.medworm.com/index.php?rid=2604439&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090715_133000 Horsham, Pa., July 15, 2009 – Based on the data presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of trabectedin when administered with DOXIL® (doxorubicin HCI liposome injection) did not provide a sufficient benefit-risk profile for the treatment of relapsed ovarian cancer..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2604439 Wed, 15 Jul 2009 07:26:18 +0100 2604439 OneTouch® Ping™ Glucose Management System Approved by Health Canada(Jul 15, 2009) http://www.medworm.com/index.php?rid=2604440&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090715_130000 Vancouver (July 15, 2009) -- Animas Corporation announced today the approval of its OneTouch® Ping™ Glucose Management System by Health Canada. OneTouch Ping is the first full-feature insulin pump that wirelessly communicates with a blood glucose meter-remote. Using the OneTouch Ping meter-remote, a person can calculate insulin doses and opt to wirelessly instruct the pump to deliver them without touching the pump at all, giving patients more freedom and flexibility in using their insulin pump..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2604440 Wed, 15 Jul 2009 07:08:53 +0100 2604440 Monitoring Circulating Tumor Cells with the Cellsearch® System Can Predict Prognosis in Metastatic Breast Cancer (Jul 13, 2009) http://www.medworm.com/index.php?rid=2596650&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090713_090000 Raritan, NJ (July 13, 2009) – Measuring the change in circulating tumor cell (CTC) count can accurately predict the prognosis and survival in patients with metastatic breast cancer (MBC), according to a newly published report in the July 10 issue of the Journal of Clinical Oncology. The retrospective study compared how well CTCs and a more sensitive than conventional modality, fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), predicted survival in MBC patients on standard therapies. The comparison showed that both technologies significantly correlate to overall MBC patient survival (p<0.001 for CTCs and p=0.001 for FDG-PET/CT). However, a CTC count of five or more could better predict the prognosis and survival in MBC patients..... (Source: Johnson and... Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2596650 Mon, 13 Jul 2009 13:34:27 +0100 2596650 Johnson & Johnson Reports 2009 Second-Quarter Results:(Jul 13, 2009) http://www.medworm.com/index.php?rid=2600108&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090714_0745 New Brunswick, NJ (July 14, 2009) – Johnson & Johnson today announced sales of $15.2 billion for the second quarter of 2009, a decrease of 7.4% as compared to the second quarter of 2008. Operational results declined 1.4% and the negative impact of currency was 6.0%. Domestic sales declined 6.7%, while international sales declined 8.0%, reflecting operational growth of 3.9% and a negative currency impact of 11.9%..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2600108 Mon, 13 Jul 2009 08:36:18 +0100 2600108 Johnson & Johnson Completes Acquisition of Cougar Biotechnology(Jul 10, 2009) http://www.medworm.com/index.php?rid=2590191&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20091009_090000   (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2590191 Fri, 10 Jul 2009 13:10:02 +0100 2590191 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results(Jul 7, 2009) http://www.medworm.com/index.php?rid=2578775&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090707_090000 New Brunswick, NJ (July 7, 2009) - Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, July 14, 2009, to review second-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President, Investor Relations, will host the call..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2578775 Tue, 07 Jul 2009 13:51:23 +0100 2578775 Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology(Jul 3, 2009) http://www.medworm.com/index.php?rid=2566745&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090703_090000 New Brunswick, N.J. (July 3, 2009) -- Johnson & Johnson (NYSE: JNJ) today announced that the initial offering period of its tender offer for all outstanding shares of common stock of Cougar Biotechnology, Inc. (NASDAQ: CGRB) expired at midnight (Eastern time) on July 2, 2009.  The offer was conducted through a wholly owned subsidiary of Johnson & Johnson named Kite Merger Sub, Inc..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2566745 Fri, 03 Jul 2009 13:48:23 +0100 2566745 Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer’s Immunotherapy Program and Equity Investment(Jul 2, 2009) http://www.medworm.com/index.php?rid=2566746&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090702_080000 New Brunswick, N.J., and Dublin, Ireland, July 2, 2009 – Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP Program), through a newly formed company.  In addition, Johnson & Johnson, through its affiliate, will invest $1 billion in Elan in exchange for newly issued American Depositary Receipts (ADRs) of Elan which will represent 18.4% of Elan’s outstanding ordinary shares..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2566746 Thu, 02 Jul 2009 13:37:29 +0100 2566746 Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research(Jul 1, 2009) http://www.medworm.com/index.php?rid=2566747&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090701_140000 London, (July 1, 2009) – (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2566747 Wed, 01 Jul 2009 07:26:00 +0100 2566747 Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories (Jun 29, 2009) http://www.medworm.com/index.php?rid=2554709&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090629_210000 Horsham, PA (June 29, 2009) – Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit. (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2554709 Mon, 29 Jun 2009 15:26:15 +0100 2554709 SIMPONI™ (Golimumab) Receives Positive Opinion from Chmp for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis(Jun 26, 2009) http://www.medworm.com/index.php?rid=2525643&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090626_100000 Horsham, PA and Kenilworth, NJ (June 25, 2009) – Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending the approval of SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS).&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2525643 Fri, 26 Jun 2009 14:26:28 +0100 2525643 Girls’ Overall Self-Worth Improves With Contact Lens Wear, Study Shows(Jun 25, 2009) http://www.medworm.com/index.php?rid=2514295&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090625_083000 Jacksonville, FL (June 25, 2009) – Contact lenses improve the overall self-worth of girls, according to data drawn from a three-year multi-site study assessing the effects of glasses and contact lenses on the self-perception of nearsighted children ages eight to 11 years. The research, a unique collaboration between psychology and optometry, further demonstrates the value-added benefits of contact lens wear beyond vision correction..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2514295 Thu, 25 Jun 2009 13:09:34 +0100 2514295 Ortho Clinical Diagnostics Opens State-Of-The-Art Manufacturing Facility In Pencoed, Wales(Jun 25, 2009) http://www.medworm.com/index.php?rid=2514296&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090625_080000 Pencoed, Wales (24 June 2009) –Ortho Clinical Diagnostics (OCD) today announced the opening of a new, state-of-the-art manufacturing facility in Pencoed, Wales. The occasion was marked by an official visit from HRH The Prince of Wales, who spoke at the opening ceremony..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2514296 Thu, 25 Jun 2009 13:05:10 +0100 2514296 NUCYNTA™ (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain (Jun 23, 2009) http://www.medworm.com/index.php?rid=2494175&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090623_080000 Raritan, NJ – June 23, 2009 – Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA™ (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe acute pain in patients 18 years of age or older is now available by prescription only in 50-mg, 75-mg and 100-mg tablets, announced PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2494175 Tue, 23 Jun 2009 12:00:00 +0100 2494175 Biosense Webster To Showcase CARTO® 3 System at EUROPACE(Jun 22, 2009) http://www.medworm.com/index.php?rid=2494176&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090622_150000 Berlin, Germany (June 21, 2009) – Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase the CARTO® 3 System, the most advanced three-dimensional imaging technology for use by electrophysiologists in treating cardiac arrhythmias, commonly referred to as irregular heart rhythms, here at EUROPACE, the official Congress of the European Heart Rhythm Association..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2494176 Mon, 22 Jun 2009 07:46:54 +0100 2494176 Unique Collaboration between TB Alliance and Tibotec to Accelerate Tuberculosis Drug Development(Jun 17, 2009) http://www.medworm.com/index.php?rid=2494178&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090617_110000 Seattle, WA (June 17, 2009) – A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec, a global pharmaceutical company, has been announced today at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to fight tuberculosis (TB).  The collaboration agreement  is between Janssen Pharmaceutica NV, an affiliate of Tibotec, and the TB Alliance..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2494178 Wed, 17 Jun 2009 16:00:00 +0100 2494178 Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition Of Cougar Biotechnology (Jun 17, 2009) http://www.medworm.com/index.php?rid=2494177&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090617_150000 New Brunswick, N.J. (June 17, 2009) -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to its previously announced planned acquisition of Cougar Biotechnology (Nasdaq: CGRB). &#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2494177 Wed, 17 Jun 2009 10:00:24 +0100 2494177 Biosense Webster to Support Landmark Clinical Trial of Atrial Fibrillation (Jun 12, 2009) http://www.medworm.com/index.php?rid=2481860&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090612_120000 Diamond Bar, CA (June 12, 2009) – Biosense Webster, Inc (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2481860 Fri, 12 Jun 2009 05:59:40 +0100 2481860 New Analysis Shows Efficacy of SIMPONI™ (GOLIMUMAB) In Anti-TNF Experienced Rheumatoid Arthritis Patients(Jun 10, 2009) http://www.medworm.com/index.php?rid=2481861&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090610_100000 Copenhagen, Denmark (June 10, 2009) - A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI™ (golimumab) once every four weeks experienced significant improvements in signs and symptoms through week 24, compared with patients receiving placebo.  Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if receiving them at baseline.  These data were presented at the 2009 European League Against Rheumatism (EULAR) Annual Congress.&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2481861 Wed, 10 Jun 2009 13:53:23 +0100 2481861 Two-Year Data Show Patients Receiving SIMPONI™ (GOLIMUMAB) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis(Jun 10, 2009) http://www.medworm.com/index.php?rid=2481862&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090610_093000 Copenhagen, Denmark (June 10, 2009) – Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) injections of SIMPONI™ (golimumab) 50 mg or 100 mg every four weeks provided persistent improvements in the signs and symptoms in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS).  Investigators reported these new data from the long term treatment extensions of the GO-REVEAL and GO-RAISE trials at the 2009 European League Against Rheumatism (EULAR) Annual Congress.&#160..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2481862 Wed, 10 Jun 2009 13:29:32 +0100 2481862 FDA Approves 12-Month Labeling Update for EVOLENCE® Collagen-Based Facial Filler (Jun 8, 2009) http://www.medworm.com/index.php?rid=2466365&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090608_100000 Herzliya, Israel and Skillman, NJ (June 8, 2009) -- Ortho Dermatologics today announced that the U.S. Food and Drug Administration (FDA) approved a labeling supplement which includes efficacy and safety data through 12 months for EVOLENCE®, a collagen-based dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2466365 Mon, 08 Jun 2009 06:27:06 +0100 2466365 Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology(Jun 5, 2009) http://www.medworm.com/index.php?rid=2466366&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090605_093000 New Brunswick, NJ (June 5, 2009) -- Johnson & Johnson (NYSE: JNJ), through a new wholly-owned subsidiary, Kite Merger Sub, Inc., today will commence a cash tender offer to purchase all outstanding shares of common stock of Cougar Biotechnology, Inc. (Nasdaq: CGRB). Johnson & Johnson reported on May 21, 2009, its intent to acquire Cougar Biotechnology..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2466366 Fri, 05 Jun 2009 16:26:49 +0100 2466366 Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer (Jun 5, 2009) http://www.medworm.com/index.php?rid=2466367&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090605_090000 Raritan, NJ (June 4, 2009)-- Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., today announced that it has entered into a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), with Steven A. Rosenberg, M.D., Ph.D., chief, Surgery Branch, serving as the NCI principal investigator, to research and develop novel cell therapy technologies as potential treatments for a variety of cancers. These adoptive immunotherapy technologies are designed to work by helping the immune system fight cancer. Standard cancer treatments still have not progressed much beyond surgery, radiation and chemotherapy, which are effective at killing tumor cells but also can harm or kill healthy tissues. Adoptive imm... Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2466367 Fri, 05 Jun 2009 16:17:52 +0100 2466367 Ethicon Endo-Surgery Studies Presented At DDW Demonstrate Potential Of Pure NOTES Surgery With Company’s Toolbox (Jun 3, 2009) http://www.medworm.com/index.php?rid=2481866&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090603_120000 Cincinnati (June 3, 2009) – Ethicon Endo-Surgery, Inc. today announced that multiple studies presented at the 2009 Digestive Disease Week (DDW) demonstrate the company’s novel, investigational*  Toolbox enables natural orifice translumenal endoscopic surgery (NOTES) procedures without laparoscopic support in porcine models.  One of the studies concluded that a new adaptable minimally-invasive surgical platform for NOTES and single-site laparoscopy (SSL) was successfully used to complete a variety of key surgical activities critical to pure natural orifice surgery and SSL..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2481866 Wed, 03 Jun 2009 16:00:00 +0100 2481866 New Tool to Improve Patient Understanding of Long-acting Injectable (LAI) Antipsychotic Therapy Unveiled (Jun 3, 2009) http://www.medworm.com/index.php?rid=2481865&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090603_113000 Beerse, Belgium (June 2, 2009) – A new tool to improve patient understanding and acceptance of long-acting injectable (LAI) antipsychotic therapy has been published for the first time in the April edition of the U.S. journal Psychiatry 2009. (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2481865 Wed, 03 Jun 2009 15:27:15 +0100 2481865 Data on Investigational Drug TMC207 for Treatment of MDR-Tuberculosis, Published In New England Journal of Medicine(Jun 3, 2009) http://www.medworm.com/index.php?rid=2481863&cid=s_37965_34_f&fid=37965&url=http%3A%2F%2Fwww.jnj.com%2Fwps%2Fwcm%2Fconnect%2Fjnj.com%2Bdevelopment%2Fdevelopment%2Fnews%2Fall%2F20090603_160000 Mechelen, Belgium (June 3, 2009) –Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA. The data show that the addition of TMC207 for eight weeks to a 5-drug background regimen, in patients with multidrug-resistant tuberculosis (MDR-TB), resulted in a significant increase in the proportion of patients achieving a negative sputum culture and a shorter time to sputum culture conversion compared with the background regimen alone..... (Source: Johnson and Johnson) Johnson and Johnson organizations http://www.medworm.com/rss/comments.php?id=2481863 Wed, 03 Jun 2009 09:49:01 +0100 2481863